FDA and psychedelics: what the public hearing notice proposed

Psiconáutica Editorial Team · September 1, 2026

The U.S. Food and Drug Administration (FDA) scheduled a public hearing for September 14, 2026, to gather input from researchers, clinicians, and the public on how the therapeutic use of psychedelics should be regulated. The notice was published in the Federal Register on July 14, 2026. The agency also published its final guidance on clinical investigations of these substances that month.

A meeting at the FDA campus

The notice provided for a hybrid session: in-person at the White Oak campus in Silver Spring, Maryland, and via live video conference for those who prefer to attend remotely. The session was scheduled for 12:30 p.m. to 4:30 p.m. (Eastern Time) and is organized by the FDA in conjunction with other federal agencies. Both attendance registration and requests to present closed on August 21; the separate written-comment deadline was October 5, 2026.

What is being debated—and what is excluded

The official notice convening the hearing details the topics on which the agency is seeking proposals: how to train and certify professionals who facilitate sessions, what safety measures should be required for patients, how to approach access to these treatments, and what standards should be followed to collect and compare data across trials. The FDA has been explicit about what is off the table: the hearing will not discuss the efficacy or safety of any specific drug, its legal classification, or the legalization or decriminalization of use outside of clinical settings. It is, therefore, a consultation focused on the medical-regulatory landscape, rather than drug policy in a broader sense.

This hearing builds upon the guidance “Psychedelic Drugs: Considerations for Clinical Investigations,” which the FDA finalized in July. That document offers laboratories concrete recommendations regarding trial design, product quality, and participant safety. The agency defines “psychedelic drugs” broadly, including psilocybin, LSD, MDMA, and related substances, establishing the framework for future approval applications.

What it implies

The move is part of an executive order signed by the U.S. administration in April, which directs federal agencies to accelerate the research and review of psychedelics as potential treatments for serious mental health conditions, explicitly mentioning the therapeutic potential of compounds like ibogaine. Having a regulatory roadmap is not the same as approval: the notice and guidance do not themselves authorise a medicine to be marketed. The significance of this hearing lies elsewhere: the agency publicly put forward specific questions—such as who should facilitate a psychedelic session and what guarantees a patient must have—with a defined public-comment period. This is a continuation of a process we previously covered when the administration received 59 proposals on how to train those professionals. These are the types of details that will eventually determine whether legal access to these therapies will be widespread or restricted to a very select few.

Source

• FDA. Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing. U.S. Food and Drug Administration, event page; official notice published in the Federal Register on July 14, 2026.

Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.